Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin.

Mori K, Hiraoka O, Ikeda M, Ariumi Y, Hiramoto A, Wataya Y, Kato N.

Hepatology. 2013 Oct;58(4):1236-44. doi: 10.1002/hep.26421. Epub 2013 Aug 19.

PMID:
23532970
2.

Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system.

Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, Kato N.

Virus Res. 2011 Apr;157(1):61-70. doi: 10.1016/j.virusres.2011.02.005. Epub 2011 Feb 12.

PMID:
21320556
3.

Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.

Satoh S, Mori K, Ueda Y, Sejima H, Dansako H, Ikeda M, Kato N.

PLoS One. 2015 Feb 20;10(2):e0118313. doi: 10.1371/journal.pone.0118313. eCollection 2015.

4.

Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.

Panigrahi R, Hazari S, Chandra S, Chandra PK, Datta S, Kurt R, Cameron CE, Huang Z, Zhang H, Garry RF, Balart LA, Dash S.

PLoS One. 2013 Aug 23;8(8):e72791. doi: 10.1371/journal.pone.0072791. eCollection 2013.

5.

New preclinical antimalarial drugs potently inhibit hepatitis C virus genotype 1b RNA replication.

Ueda Y, Takeda M, Mori K, Dansako H, Wakita T, Kim HS, Sato A, Wataya Y, Ikeda M, Kato N.

PLoS One. 2013 Aug 30;8(8):e72519. doi: 10.1371/journal.pone.0072519. eCollection 2013. Erratum in: PLoS One. 2013;8(9). doi:10.1371/annotation/6e1f1f8f-c421-4def-aaf1-4ce7f4915d87.

6.

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.

Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM.

Hepatology. 2003 Oct;38(4):869-78.

PMID:
14512874
7.

ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.

Iikura M, Furihata T, Mizuguchi M, Nagai M, Ikeda M, Kato N, Tsubota A, Chiba K.

Antimicrob Agents Chemother. 2012 Mar;56(3):1407-13. doi: 10.1128/AAC.05762-11. Epub 2012 Jan 9.

8.

Plural assay systems derived from different cell lines and hepatitis C virus strains are required for the objective evaluation of anti-hepatitis C virus reagents.

Ueda Y, Mori K, Ariumi Y, Ikeda M, Kato N.

Biochem Biophys Res Commun. 2011 Jun 17;409(4):663-8. doi: 10.1016/j.bbrc.2011.05.061. Epub 2011 May 17.

10.

Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.

Qashqari H, Al-Mars A, Chaudhary A, Abuzenadah A, Damanhouri G, Alqahtani M, Mahmoud M, El Sayed Zaki M, Fatima K, Qadri I.

Infect Genet Evol. 2013 Oct;19:113-9. doi: 10.1016/j.meegid.2013.06.025. Epub 2013 Jul 5. Review.

PMID:
23831932
11.

Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture.

Felmlee DJ, Xiao F, Baumert TF.

Hepatology. 2013 Oct;58(4):1203-6. doi: 10.1002/hep.26493. Epub 2013 Aug 22. No abstract available.

PMID:
23703706
12.

Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.

Ibarra KD, Jain MK, Pfeiffer JK.

J Virol. 2011 Jul;85(14):7273-83. doi: 10.1128/JVI.00629-11. Epub 2011 May 4.

13.

Ribavirin enhances the action of interferon-α against hepatitis C virus by promoting the p53 activity through the ERK1/2 pathway.

Liu WL, Yang HC, Su WC, Wang CC, Chen HL, Wang HY, Huang WH, Chen DS, Lai MY.

PLoS One. 2012;7(9):e43824. doi: 10.1371/journal.pone.0043824. Epub 2012 Sep 4.

14.

Ribavirin regulates hepatitis C virus replication through enhancing interferon-stimulated genes and interleukin 8.

Tokumoto Y, Hiasa Y, Uesugi K, Watanabe T, Mashiba T, Abe M, Kumagi T, Ikeda Y, Matsuura B, Onji M.

J Infect Dis. 2012 Apr 1;205(7):1121-30. doi: 10.1093/infdis/jis025. Epub 2012 Feb 21.

PMID:
22357660
15.

Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance.

Ibarra KD, Pfeiffer JK.

J Virol. 2009 May;83(9):4538-47. doi: 10.1128/JVI.02280-08. Epub 2009 Feb 25.

16.

Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.

El-Shamy A, Shoji I, Saito T, Watanabe H, Ide YH, Deng L, Kawata S, Hotta H.

Microbiol Immunol. 2011 Jun;55(6):418-26. doi: 10.1111/j.1348-0421.2011.00331.x.

17.

Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?

Galmozzi E, Aghemo A, Colombo M.

Med Hypotheses. 2012 Oct;79(4):471-3. doi: 10.1016/j.mehy.2012.06.026. Epub 2012 Jul 21.

PMID:
22824093
18.

Anti-HCV activity of the Chinese medicinal fungus Cordyceps militaris.

Ueda Y, Mori K, Satoh S, Dansako H, Ikeda M, Kato N.

Biochem Biophys Res Commun. 2014 May 2;447(2):341-5. doi: 10.1016/j.bbrc.2014.03.150. Epub 2014 Apr 12.

PMID:
24726408
19.

Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin.

Hmwe SS, Aizaki H, Date T, Murakami K, Ishii K, Miyamura T, Koike K, Wakita T, Suzuki T.

Antiviral Res. 2010 Mar;85(3):520-4. doi: 10.1016/j.antiviral.2009.12.008. Epub 2010 Jan 4.

PMID:
20043953
20.

Mathematical modeling of HCV infection and treatment.

Dahari H, Shudo E, Ribeiro RM, Perelson AS.

Methods Mol Biol. 2009;510:439-53. doi: 10.1007/978-1-59745-394-3_33.

PMID:
19009281

Supplemental Content

Support Center